Literature DB >> 686038

Coccidioidomycosis in potentially compromised hosts: the effect of immunosuppressive therapy in dissemination.

P J Rutala, J W Smith.   

Abstract

Charts of 126 patients with coccidioidomycosis were reviewed. Sixteen of these were patients who had malignancies, uremia, or a collagen-vascular disease and/or had received recent immunosuppressive drug therapy. The rate of disseminated infection was 50% in this group. (The dissemination rate was 14% in 110 control patients.) No case of dissemination occurred in patients who only had the above underlying diseases; all cases of dissemination were among those who had received immunosuppressive therapy. The dissemination rate in control patients was higher for patients age 40 or over than for younger patients. The dissemination rate showed no age-related difference, however, in patients treated with immunosuppressive drugs. The dissemination rate was similar in control patients of both sexes and uniformly higher for both immunosuppressively treated males and females. The dissemination rate did not appear to be influenced by the number of circulating lymphocytes if the patient had received immunosuppressive drugs. Patients with disseminated disease who had received immunosuppressive drugs were capable of producing a serological response to the coccidoiidal organism in high titer but none had positive skin test reactivity. Disseminated coccidioidomycosis is not uniformly fatal in the immunosuppressed host: half of our patients are alive an average of 33 months after diagnosis.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 686038     DOI: 10.1097/00000441-197805000-00006

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  15 in total

1.  Acute pulmonary paracoccidioidomycosis in an immunosuppressed patient.

Authors:  L C Severo; A T Londero; G R Geyer; N S Porto
Journal:  Mycopathologia       Date:  1979-09-28       Impact factor: 2.574

2.  Reactivation of coccidioides infection.

Authors:  J Seltzer; V C Broaddus; R Jacobs; J A Golden
Journal:  West J Med       Date:  1986-07

3.  Hospitalized burden and outcomes of coccidioidomycosis: A nationwide analysis, 2005-2012.

Authors:  Ruihong Luo; Alan Greenberg; Christian D Stone
Journal:  Med Mycol       Date:  2017-06-01       Impact factor: 4.076

4.  Disseminated coccidioidomycosis in an immunocompetent person living in New York City.

Authors:  Amy Chuang; Reeni Thomas; Robert S Hoffman
Journal:  J Urban Health       Date:  2005-05-12       Impact factor: 3.671

5.  Serologic testing for symptomatic coccidioidomycosis in immunocompetent and immunosuppressed hosts.

Authors:  Janis E Blair; Brandon Coakley; Ana C Santelli; Joseph G Hentz; Nancy L Wengenack
Journal:  Mycopathologia       Date:  2006-11       Impact factor: 2.574

Review 6.  Coccidioidomycosis.

Authors:  J N Galgiani
Journal:  West J Med       Date:  1993-08

7.  Coccidioidomycosis: evaluation of parameters used to predict outcome with amphotericin B therapy.

Authors:  M H Hardenbrook; S L Barriere
Journal:  Mycopathologia       Date:  1982-05-22       Impact factor: 2.574

Review 8.  Paracoccidioidomycosis: an update.

Authors:  E Brummer; E Castaneda; A Restrepo
Journal:  Clin Microbiol Rev       Date:  1993-04       Impact factor: 26.132

9.  Reactivity to spherule-derived coccidioidin in the southeastern United States.

Authors:  W W Woodruff; C E Buckley; H A Gallis; J R Cohn; R W Wheat
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

10.  Coccidioidomycosis in Allogeneic Stem Cell Transplant Recipients: Case Series and Review of the Literature.

Authors:  Christopher F Saling; Juan Gea-Banacloche; John S Trickett; Janis E Blair
Journal:  J Fungi (Basel)       Date:  2021-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.